A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Inclusion criteria

• Willing and able to provide written informed consent for the trial
• ≥ 18 years of age
• Histologically- or cytologically- confirmed locally advanced or metastatic WDNET
• SSA therapy is recommended by physician for disease management, and has not yet begun
• ECOG performance status of 0, 1, or 2

Exclusion criteria

• Currently participating in a study of an investigational agent
• Prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent

*Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study

• No concurrent chemotherapy or targeted small molecule therapy
• If received major surgery, not recovered adequately from the toxicity and/or complications from the intervention prior to starting the study
• Known additional malignancy that is progressing or requires active treatment
• Active infection requiring systemic therapy
• Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial